Applied Molecular Transport, LLC

51 articles about Applied Molecular Transport, LLC

• Applied Molecular Transport Reports Third Quarter 2023 Financial Results

  11/9/2023

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023.

• Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

  9/21/2023

  Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1).

• Applied Molecular Transport Reports Second Quarter 2023 Financial Results

  8/14/2023

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023.

• Applied Molecular Transport Reports First Quarter 2023 Financial Results

  5/11/2023

  Applied Molecular Transport Inc., a biopharmaceutical company, reported financial results for the first quarter ended March 31, 2023.

• Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives

  3/27/2023

  Applied Molecular Transport Inc. announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company.

• Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/9/2023

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.

• Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress

  3/3/2023

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, which is also in development for the treatment of rheumatoid arthritis (RA).

• Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

  12/22/2022

  Applied Molecular Transport Inc. announced top-line Phase 2 results from the LOMBARD monotherapy trial for AMT-101 in biologic-naïve and experienced patients with moderate-to-severe ulcerative colitis.

• Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis

  11/10/2022

  Applied Molecular Transport Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for AMT-101 in patients with pouchitis, an indication with significant unmet medical need and no current FDA-approved products.

• Applied Molecular Transport to Present at Upcoming November 2022 Investor Conferences

  11/8/2022

  Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced its participation at the following investor conferences.

• Applied Molecular Transport Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/7/2022

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

• Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/4/2022

  Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

• 

  Applied Molecular Transport's UC Candidate Proves Effective in Early-Stage Intervention

  7/6/2022

  In patients stricken with ulcerative colitis for less than five years, AMT-101 was nearly three times more effective in inducing clinical remission than the placebo after eight weeks.

• Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

  7/6/2022

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced top-line Phase 2 results from the MARKET combination trial for AMT-101 in biologic-naïve patients with moderate-to-severe UC.

• Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

  7/5/2022

  Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis.

• Applied Molecular Transport to Present at Upcoming June 2022 Investor Conferences

  6/2/2022

  Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced its participation in fireside chats at the following investor conferences.

• 

  Applied Molecular Transport Shifts Gear, Cuts Workforce by 40%

  5/18/2022

  Applied Molecular Transport (AMT) provided a strategy update on Wednesday. Part of the update includes reducing its workforce by about 40% and funneling resources into its lead program.

• Applied Molecular Transport Provides Strategy Update

  5/18/2022

  Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced strategic actions to focus resources on its lead clinical programs.

• Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference

  5/5/2022

  Applied Molecular Transport Inc. will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET.

• 

  Clinical Catch-Up: Genentech Announces Positive Data, Pfizer Develops New Vaccine

  5/2/2022

  A roundup of last week's top clinical trial updates and news.